Checkmate 227 Reveals Six-Year Survival Advantages of Nivolumab + Ipilimumab in mNSCLC Non-Small Cell Lung Cancer 2 Mins Read3 In a conversation hosted by Allen Wilbanks, Solange Peters, MD, PhD, a full professor and chair of medical oncology specializing…
